{
    "root": "f0bead0e-4eed-4db9-a076-1d974eba6b4a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FABHALTA",
    "value": "20250320",
    "ingredients": [
        {
            "name": "IPTACOPAN HYDROCHLORIDE",
            "code": "XW5CK7C6YH"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "fabhalta complement factor b inhibitor , indicated : treatment adults paroxysmal nocturnal hemoglobinuria ( pnh ) . ( 1.1 ) reduction proteinuria adults primary immunoglobulin nephropathy ( igan ) risk rapid disease progression , generally urine protein-to-creatinine ratio ( upcr ) \u2265 1.5 g/g . ( 1.2 ) indication approved accelerated approval based reduction proteinuria . established whether fabhalta slows kidney function decline patients igan . continued approval indication may contingent upon verification description benefit confirmatory trial . treatment adults complement 3 glomerulopathy ( c3g ) , reduce proteinuria . ( 1.3 )",
    "contraindications": "200 mg orally twice daily without food . ( 2.2 )",
    "warningsAndPrecautions": "200 mg capsules : pale yellow opaque hard capsules , imprinted \u201c lnp200 \u201d one half \u201c nvr \u201d half , packaged high-density polyethylene ( hdpe ) bottle induction seal child-resistant cap . bottle contains 60 capsules ( ndc 0078-1189-20 ) . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "fabhalta contraindicated : patients serious hypersensitivity iptacopan excipients . initiation patients unresolved serious infection caused encapsulated bacteria , including streptococcus pneumoniae , neisseria meningitidis , haemophilus influenzae type b .",
    "indications_original": "FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) \u2265 1.5 g/g. ( 1.2 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 )",
    "contraindications_original": "200 mg orally twice daily with or without food. ( 2.2 )",
    "warningsAndPrecautions_original": "200 mg capsules: pale yellow opaque hard capsules, imprinted with \u201cLNP200\u201d on one half and \u201cNVR\u201d on the other half, packaged in a high-density polyethylene (HDPE) bottle with induction seal and child-resistant cap. Each bottle contains 60 capsules (NDC 0078-1189-20).\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "FABHALTA is contraindicated:\n                  \n                     in patients with serious hypersensitivity to iptacopan or any of the excipients.\n                     for initiation in patients with unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b."
}